Immunotherapy in Lymphoma (NCT06796517) | Clinical Trial Compass
RecruitingNot Applicable
Immunotherapy in Lymphoma
South Korea72 participantsStarted 2024-06-26
Plain-language summary
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:
Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?
Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.
Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
Who can participate
Age range
19 Years – 74 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 19 to 74 years.
* Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
* Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma
Exclusion Criteria:
* Patients who have progressed to acute leukemia
* Patients who developed solid tumor during treatment
* Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is studying overall survival in relapsed or refractory high-grade B-cell lymphoma — meaning the cancer has come back or stopped responding to treatment — does my specific situation match what this trial is looking for, and is this the right point in my treatment journey to consider it?
2This trial is listed as Phase 'NA,' which is unusual — can you help me understand what that means for how much is already known about the safety and effectiveness of the immunotherapy approach being used here?
3Given that this trial covers several related but distinct diagnoses, including Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Burkitt Lymphoma, does the specific type I have fit what researchers are targeting, and would that affect what I might experience on the trial?
4Since the main thing being measured is overall survival, what does that tell us about where this research is in terms of understanding whether this immunotherapy approach actually helps patients live longer compared to other options I might have?
5Before we consider this trial, are there standard treatment options — like salvage chemotherapy or CAR-T cell therapy — that you would recommend I try first, or is participating in this study something worth discussing as an alternative right now?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall survival
Timeframe: From the start of treatment or the date of study enrollment until death from any cause, assessed up to 100 months.